MA46945A - Exopolysaccharides et leurs utilisations - Google Patents

Exopolysaccharides et leurs utilisations

Info

Publication number
MA46945A
MA46945A MA046945A MA46945A MA46945A MA 46945 A MA46945 A MA 46945A MA 046945 A MA046945 A MA 046945A MA 46945 A MA46945 A MA 46945A MA 46945 A MA46945 A MA 46945A
Authority
MA
Morocco
Prior art keywords
exopolysaccharides
Prior art date
Application number
MA046945A
Other languages
English (en)
Inventor
Silvia Balzaretti
Andrea Biffi
Walter Fiore
Simone Domenico Guglielmetti
Ruggero Rossi
Original Assignee
Sofar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sofar Spa filed Critical Sofar Spa
Publication of MA46945A publication Critical patent/MA46945A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MA046945A 2016-12-02 2017-12-01 Exopolysaccharides et leurs utilisations MA46945A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102016000122724A IT201600122724A1 (it) 2016-12-02 2016-12-02 Exopolysaccharides and uses thereof

Publications (1)

Publication Number Publication Date
MA46945A true MA46945A (fr) 2021-03-17

Family

ID=58609750

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046945A MA46945A (fr) 2016-12-02 2017-12-01 Exopolysaccharides et leurs utilisations

Country Status (11)

Country Link
US (1) US11591416B2 (fr)
EP (1) EP3548630A1 (fr)
CN (1) CN110191957B (fr)
AU (2) AU2017367302B2 (fr)
BR (1) BR112019010867A2 (fr)
CL (1) CL2019001493A1 (fr)
CO (1) CO2019007116A2 (fr)
IT (1) IT201600122724A1 (fr)
MA (1) MA46945A (fr)
MX (1) MX2019006406A (fr)
WO (1) WO2018100549A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
IT201600083376A1 (it) 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
AU2020287268B2 (en) * 2019-06-05 2026-02-19 Lac2biome S.r.l. Compositions comprising a bacterial strain lactobacillus paracasei and hyaluronic acid and the use thereof for the treatment of the skin
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517363A (ja) 1991-07-11 1993-01-26 Yakult Honsha Co Ltd 抗炎症剤及びそれを含有する化粧料
CN1066926C (zh) 1996-04-08 2001-06-13 钟春燕 将椰子水发酵制作的食用纤维及其生产方法
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CZ9900769A3 (cs) 1999-03-04 2000-10-11 Petr Ing. Drsc. Hušek Použití špičky s filtrem k vytvoření sloupce sorbentu s definovaným objemem v prostoru pod filtrem
US20020090416A1 (en) 1999-03-09 2002-07-11 Philip Connolly Method of enhancing absorption and utilization of protein
IT1307850B1 (it) 1999-03-15 2001-11-19 Italmed Di Galli Giovanna E Pa Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio
EP1145643A1 (fr) 2000-04-10 2001-10-17 Phillip Connolly Concentré de lactoprotéines amelioré
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
RU2182008C1 (ru) 2000-10-20 2002-05-10 Самойленко Игорь Иннокентьевич Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
FI20020078A7 (fi) 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
US6881419B2 (en) 2002-04-09 2005-04-19 William E. Lovett Vitamin formulation for enhancing bone strength
EP1539192A1 (fr) 2002-04-24 2005-06-15 Medicarb AB Composition et ensemble de traitement de maladies intestinales inflammatoires
NZ537499A (en) * 2002-08-06 2007-01-26 Danisco Use of lactobacillus to produce exopolysaccharides in food and pharmaceutical compositions
AU2002951270A0 (en) 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
WO2005001109A2 (fr) 2003-05-06 2005-01-06 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Procedes et compositions permettant de detecter des microbes dans des echantillons fecaux
US20100112088A1 (en) 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
WO2005083122A2 (fr) 2004-02-27 2005-09-09 Stichting Laboratorium Voor Infectieziekten Methode de detection de micro-organisme dans un echantillon fecal
CA2557834C (fr) 2004-03-04 2012-05-22 E-L Management Corporation Methode de traitement de la peau au moyen d'extrait de lactobacillus
US20090197249A1 (en) 2004-11-01 2009-08-06 George Mason University Compositions and methods for diagnosing colon disorders
DK1868454T3 (da) 2005-04-06 2013-04-02 Nestec Sa Sammensætning til ernæringsmæssig forbedring af glucosekontrol og insulinvirkning
FI20051319A7 (fi) 2005-12-22 2007-06-23 Gut Guide Oy Menetelmä eläimen ja/tai ihmisen ravitsemuksen ja hyvinvoinnin ja eläinten tuottavuuden seuraamiseksi ja kehittämiseksi
CN1840206A (zh) 2006-01-19 2006-10-04 上海交通大学 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法
EP1997886B1 (fr) 2006-02-21 2013-06-05 National University Corporation University of Toyama Procédé rapide d'identification du microorganisme responsable d'une maladie infectieuse
JP5289936B2 (ja) 2006-02-24 2013-09-11 キユーピー株式会社 新規な低分子ヒアルロン酸および／またはその塩、ならびにこれを用いた化粧料、医薬組成物および食品組成物
WO2007140621A1 (fr) 2006-06-09 2007-12-13 Nutravital Inc. Compositions probiotiques et leurs utilisations
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
US20080081035A1 (en) 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
WO2008076975A1 (fr) 2006-12-18 2008-06-26 Advanced Bionutrition Corporation Produit alimentaire sec contenant un probiotique vivant
EP1972208A1 (fr) 2007-03-16 2008-09-24 Kirin Holdings Kabushiki Kaisha Composition pour améliorer la flore microbienne intestinale
RU2009133376A (ru) 2007-03-27 2011-05-10 Дзе Проктер Энд Гэмбл Компани (US) Способы и наборы для введения пробиотиков
EP2176299B1 (fr) * 2007-05-04 2017-07-05 Alimentary Health Limited Exopolysaccharide obtenu de bifidobacterium infantis 35624 (ncimb 41003)
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US20110014167A1 (en) 2007-07-06 2011-01-20 N.V. Nutricia Use of probiotics and fibers for diarrhoea
US8193155B2 (en) 2009-02-09 2012-06-05 Elc Management, Llc Method and compositions for treating skin
US20090098088A1 (en) 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
CN101240315A (zh) 2008-02-21 2008-08-13 上海交通大学 检测药物防癌效果的非损伤性分子方法
EP2318513B1 (fr) * 2008-07-11 2012-09-19 Chr. Hansen A/S Nouveau bifidobacterium longum probiotique
WO2010008272A1 (fr) 2008-07-15 2010-01-21 N.V. Nutricia Traitement de troubles du transit intestinal
JP2010161944A (ja) 2009-01-13 2010-07-29 Syngen Biotech Co Ltd 新型カゼイ菌の亜種（ｓｇ９６）及びこれを含有する菌抑制組成物及びその用途
AU2009341473B2 (en) 2009-03-05 2016-04-21 Probiotical S.P.A. Bacteria strains having a high anti-inflammatory activity
WO2010103132A1 (fr) 2009-03-10 2010-09-16 Hero España, S.A. Isolement, identification et caractérisation de souches ayant une activité probiotique à partir de fèces de nourrissons alimentés exclusivement avec du lait maternel
JP2013505289A (ja) 2009-09-23 2013-02-14 トーマス・ジュリアス・ボロディ 腸管感染症の治療法
JP6006117B2 (ja) 2009-11-12 2016-10-12 ネステク ソシエテ アノニム 腸内微生物叢バランス及び健康を促進するための栄養組成物
CA2784723C (fr) 2009-12-22 2021-01-12 Probi Ab Compositions non fermentees comprenant une fraction a base de cereales et un probiotique et des utilisations de celles-ci
US8575130B2 (en) 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
ITUD20100112A1 (it) 2010-06-09 2011-12-10 Farma Derma S R L Preparazione per uso vaginale e rettale e relativo procedimento di produzione
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
WO2012154738A1 (fr) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition et procédé pour améliorer la santé intestinale
CA2848471C (fr) * 2011-09-23 2021-11-16 Actogenix Nv Bacteries gram positif modifiees et leurs utilisations
GB201219873D0 (en) 2012-11-05 2012-12-19 Multigerm Uk Entpr Ltd Diverticulitis treatment
CN102919922A (zh) 2012-11-08 2013-02-13 黑龙江省轻工科学研究院 一种复合益生菌发酵蓝莓果汁粉的制备方法
MX2015011700A (es) 2013-03-05 2016-07-20 Univ Groningen Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion.
BR112015032918B1 (pt) 2013-07-02 2021-09-28 Austrianova Singapore Pte Ltd Métodos para preparação de células encapsuladas para liofilização, composição e seus usos
ITMI20131473A1 (it) * 2013-09-06 2015-03-07 Sofar Spa Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
WO2015172191A1 (fr) 2014-05-12 2015-11-19 Medlab Ip Pty Ltd Compositions probiotiques et leurs utilisations pour le traitement de troubles liés à l'obésité
DK2990045T3 (en) 2014-08-26 2017-02-13 Chr Hansen As Bifidobacterium animalis subsp. lactis for use in reducing abdominal pain in a postmenopausal woman
WO2017195182A1 (fr) 2016-05-13 2017-11-16 Sofar S.P.A. Utilisation de probiotiques pour améliorer l'absorption des protéines
IT201600083376A1 (it) 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
RU2744271C2 (ru) 2016-12-16 2021-03-04 Компани Жервэ Данон Пробиотическая композиция, содержащая штаммы Lactobacillus rhamnosus и Lactobacillus paracasei
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
WO2019019961A1 (fr) 2017-07-26 2019-01-31 海思科医药集团股份有限公司 Microflore destinée à la prévention et au traitement d'une réaction du tube digestif et/ou de la peau et son utilisation
IT201700101704A1 (it) 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
AU2018378419B2 (en) 2017-12-06 2025-01-09 Lac2biome S.r.l. Composition based on probiotics and uses thereof
CN108743851A (zh) 2018-08-09 2018-11-06 深圳市博奥生物科技有限公司 一种复合益生菌粉的制备方法及复合益生菌粉
IT201900016850A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e estratti di bacche e loro uso come antinfiammatori
IT201900016805A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900016865A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e loro uso come antinfiammatori
IT201900016811A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900020422A1 (it) 2019-11-05 2021-05-05 Sofar Spa Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems

Also Published As

Publication number Publication date
CO2019007116A2 (es) 2019-09-09
AU2017367302B2 (en) 2022-07-28
WO2018100549A1 (fr) 2018-06-07
AU2022204885A1 (en) 2022-07-28
BR112019010867A2 (pt) 2019-10-22
US11591416B2 (en) 2023-02-28
IT201600122724A1 (it) 2018-06-02
MX2019006406A (es) 2019-08-14
US20190345268A1 (en) 2019-11-14
CL2019001493A1 (es) 2019-08-30
CN110191957B (zh) 2023-07-28
CN110191957A (zh) 2019-08-30
EP3548630A1 (fr) 2019-10-09
AU2017367302A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
MA50618A (fr) Polyrhérapies et leurs utilisations
EP3732201A4 (fr) Molécules de substitution de wnt et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3349802A4 (fr) Dendrimères lipocationiques et leurs utilisations
EP3471727A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
MA46471A (fr) Protéines actriib à variant et leurs utilisations
EP3490565A4 (fr) Modulateurs de récepteurs de chimiokine et leurs utilisations
EP3472129A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3352776A4 (fr) Répresseurs htt et leurs utilisations
EP3334706A4 (fr) Pillararènes et utilisations de ceux-ci
MA53400A (fr) Hétéromultimères alk7: actriib et leurs utilisations
EP3283517A4 (fr) Anticorps anti-pacap et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
EP3538261A4 (fr) Catalyseurs en pérovskite et leurs utilisations
EP3370528A4 (fr) Compositions probiotiques et leurs utilisations
EP3347021A4 (fr) Cyano-thiénotriazoloazépines et leurs utilisations
EP3471726A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3347020A4 (fr) Acétamide thiénotriazoldiazépines et leurs utilisations
EP3341007A4 (fr) Inhibiteurs de malt1 et leurs utilisations
EP3370771A4 (fr) Conjugués anti-cd3-folate et leurs utilisations
MA46901A (fr) Agents psychotropes et leurs utilisations
EP3432859A4 (fr) Compositions cosmétiques et leurs utilisations
EP3664799A4 (fr) Antibiotiques linconsamides et leurs utilisations